Veru to Present at the American Diabetes Association’s 84th Scientific Sessions
MIAMI, FL, June 10, 2024 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two presentations at the American Diabetes Association’s 84th Scientific Sessions, taking place June 21-24, 2024, in Orlando, Florida.